Dendreon Corp fka DNDNQ

[mhigg]

So, P3, are you refering to this theory from ocyan:

"Now, if they successfully get the FDA to agree to OBF, then a really neat phenomenon happens. The OBF method gives the nominal alpha for the interim higher and higher value depending on how close it gets to the final trigger. Therefore, by lowering the final trigger and increasing the interim trigger at the same time, the nominal alpha could become higher than before and enhancing the chance of the interim meeting stat sig.

The risk in reducing the trigger for the final is that it reduces the power of the trial over all."